MedPath

PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg

Completed
Conditions
Hypertension
Registration Number
NCT00936208
Lead Sponsor
Boehringer Ingelheim
Brief Summary

PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular events. The study aims to evaluate the safety, efficacy and protection of Micardis 80mg/Micardis plus 80/12.5mg from cardiovascular risks in patients with essential hypertension

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
3184
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in Diastolic Blood Pressure From Baseline at Week 24Baseline and Week 24

The change from baseline reflects the week 24 value minus the baseline value.

Change in Systolic Blood Pressure From Baseline at Week 24Baseline and Week 24

The change from baseline reflects the week 24 value minus the baseline value.

Secondary Outcome Measures
NameTimeMethod
Framingham Score at Week 24Week 24

The Framingham score represent the cardiovascular risk and ranges from 0 (no risk) to 100% (complete risk).

Change in the Framingham Score From Baseline at Week 24Baseline and Week 24

The change from baseline reflects the week 24 value minus the baseline value. The Framingham score represent the cardiovascular risk and ranges from 0 (no risk) to 100% (complete risk).

International Renal Interest Society (IRIS) II Score at Week 24Week 24

The IRIS II score represent the risk for vascular complication in type to diabetes mellitus and ranges from 0 (no risk) to 100% (complete risk).

Change in the IRIS II Score From Baseline at Week 24Baseline and Week 24

The change from baseline reflects the week 24 value minus the baseline value. The IRIS II score represent the risk for vascular complication in type to diabetes mellitus and ranges from 0 (no risk) to 100% (complete risk).

Change From Baseline in Urinary Microalbuminuria (Urine Dipstick Test Results)Baseline and Week 24

The change from baseline reflects the shift from baseline in urinary dipstick test results to week 24

Trial Locations

Locations (120)

Boehringer Ingelheim Investigational Site 16

πŸ‡ͺπŸ‡¬

Alexandria West, Egypt

Boehringer Ingelheim Investigational Site 21

πŸ‡ͺπŸ‡¬

Alexandria, Egypt

Boehringer Ingelheim Investigational Site 12

πŸ‡ͺπŸ‡¬

Cairo, Egypt

Boehringer Ingelheim Investigational Site 28

πŸ‡ͺπŸ‡¬

Fayoum, Egypt

Boehringer Ingelheim Investigational Site 94

πŸ‡ΈπŸ‡¦

Eastern Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 35

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 40

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 38

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 45

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 48

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 55

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 60

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 33

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 43

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 46

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 50

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 51

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 57

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 58

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 84

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 104

πŸ‡¦πŸ‡ͺ

Dubai, United Arab Emirates

Boehringer Ingelheim Investigational Site 106

πŸ‡¦πŸ‡ͺ

Dubai, United Arab Emirates

Boehringer Ingelheim Investigational Site 108

πŸ‡¦πŸ‡ͺ

Dubai, United Arab Emirates

Boehringer Ingelheim Investigational Site 111

πŸ‡¦πŸ‡ͺ

Dubai, United Arab Emirates

Boehringer Ingelheim Investigational Site 20

πŸ‡ͺπŸ‡¬

Alexandria, Egypt

Boehringer Ingelheim Investigational Site 29

πŸ‡ͺπŸ‡¬

Assiut, Egypt

Boehringer Ingelheim Investigational Site 10

πŸ‡ͺπŸ‡¬

Cairo, Egypt

Boehringer Ingelheim Investigational Site 11

πŸ‡ͺπŸ‡¬

Cairo, Egypt

Boehringer Ingelheim Investigational Site 1

πŸ‡ͺπŸ‡¬

Cairo, Egypt

Boehringer Ingelheim Investigational Site 3

πŸ‡ͺπŸ‡¬

Cairo, Egypt

Boehringer Ingelheim Investigational Site 4

πŸ‡ͺπŸ‡¬

Cairo, Egypt

Boehringer Ingelheim Investigational Site 5

πŸ‡ͺπŸ‡¬

Cairo, Egypt

Boehringer Ingelheim Investigational Site 6

πŸ‡ͺπŸ‡¬

Cairo, Egypt

Boehringer Ingelheim Investigational Site 8

πŸ‡ͺπŸ‡¬

Cairo, Egypt

Boehringer Ingelheim Investigational Site 9

πŸ‡ͺπŸ‡¬

Cairo, Egypt

Boehringer Ingelheim Investigational Site 25

πŸ‡ͺπŸ‡¬

Fakous - El Sharkia, Egypt

Boehringer Ingelheim Investigational Site 15

πŸ‡ͺπŸ‡¬

El Minia, Egypt

Boehringer Ingelheim Investigational Site 24

πŸ‡ͺπŸ‡¬

Poert said, Egypt

Boehringer Ingelheim Investigational Site 26

πŸ‡ͺπŸ‡¬

Zagazig - El Sharkia, Egypt

Boehringer Ingelheim Investigational Site 101

πŸ‡ΈπŸ‡¦

Eastern Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 92

πŸ‡ΈπŸ‡¦

Eastern Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 93

πŸ‡ΈπŸ‡¦

Eastern Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 97

πŸ‡ΈπŸ‡¦

Eastern Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 98

πŸ‡ΈπŸ‡¦

Eastern Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 96

πŸ‡ΈπŸ‡¦

Eastern Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 99

πŸ‡ΈπŸ‡¦

Eastern Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 31

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 36

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 37

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 34

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 30

πŸ‡ͺπŸ‡¬

Menofia, Egypt

Boehringer Ingelheim Investigational Site 95

πŸ‡ΈπŸ‡¦

Eastern Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 42

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 49

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 52

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 59

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 63

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 70

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 74

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 77

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 27

πŸ‡ͺπŸ‡¬

Mansoura - El Dakahlia, Egypt

Boehringer Ingelheim Investigational Site 32

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 2

πŸ‡ͺπŸ‡¬

Cairo, Egypt

Boehringer Ingelheim Investigational Site 7

πŸ‡ͺπŸ‡¬

Cairo, Egypt

Boehringer Ingelheim Investigational Site 23

πŸ‡ͺπŸ‡¬

El Garbia, Egypt

Boehringer Ingelheim Investigational Site 14

πŸ‡ͺπŸ‡¬

El Minia, Egypt

Boehringer Ingelheim Investigational Site 13

πŸ‡ͺπŸ‡¬

Kalioubya, Egypt

Boehringer Ingelheim Investigational Site 39

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 44

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 47

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 53

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 61

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 62

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 66

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 67

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 75

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 80

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 81

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 82

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 88

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 90

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 116

πŸ‡¦πŸ‡ͺ

Abu Dhabi, United Arab Emirates

Boehringer Ingelheim Investigational Site 120

πŸ‡¦πŸ‡ͺ

Abu Dhabi, United Arab Emirates

Boehringer Ingelheim Investigational Site 17

πŸ‡ͺπŸ‡¬

Alexandria West, Egypt

Boehringer Ingelheim Investigational Site 100

πŸ‡ΈπŸ‡¦

Eastern Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 41

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 56

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 68

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 83

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 85

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 87

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 91

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 114

πŸ‡¦πŸ‡ͺ

Abu Dhabi, United Arab Emirates

Boehringer Ingelheim Investigational Site 107

πŸ‡¦πŸ‡ͺ

Dubai, United Arab Emirates

Boehringer Ingelheim Investigational Site 110

πŸ‡¦πŸ‡ͺ

Dubai, United Arab Emirates

Boehringer Ingelheim Investigational Site 18

πŸ‡ͺπŸ‡¬

Alexandria, Egypt

Boehringer Ingelheim Investigational Site 19

πŸ‡ͺπŸ‡¬

Alexandria, Egypt

Boehringer Ingelheim Investigational Site 22

πŸ‡ͺπŸ‡¬

Domiat, Egypt

Boehringer Ingelheim Investigational Site 54

πŸ‡ΈπŸ‡¦

Riyadh, Saudi Arabia

Boehringer Ingelheim Investigational Site 64

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 65

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 71

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 72

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 73

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 76

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 78

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 79

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 117

πŸ‡¦πŸ‡ͺ

Abu Dhabi, United Arab Emirates

Boehringer Ingelheim Investigational Site 119

πŸ‡¦πŸ‡ͺ

Abu Dhabi, United Arab Emirates

Boehringer Ingelheim Investigational Site 102

πŸ‡¦πŸ‡ͺ

Dubai, United Arab Emirates

Boehringer Ingelheim Investigational Site 103

πŸ‡¦πŸ‡ͺ

Dubai, United Arab Emirates

Boehringer Ingelheim Investigational Site 109

πŸ‡¦πŸ‡ͺ

Dubai, United Arab Emirates

Boehringer Ingelheim Investigational Site 69

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 86

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 115

πŸ‡¦πŸ‡ͺ

Abu Dhabi, United Arab Emirates

Boehringer Ingelheim Investigational Site 105

πŸ‡¦πŸ‡ͺ

Dubai, United Arab Emirates

Boehringer Ingelheim Investigational Site 89

πŸ‡ΈπŸ‡¦

Western Region, Saudi Arabia

Boehringer Ingelheim Investigational Site 113

πŸ‡¦πŸ‡ͺ

Abu Dhabi, United Arab Emirates

Boehringer Ingelheim Investigational Site 118

πŸ‡¦πŸ‡ͺ

Abu Dhabi, United Arab Emirates

Boehringer Ingelheim Investigational Site 112

πŸ‡¦πŸ‡ͺ

Sharjah, United Arab Emirates

Β© Copyright 2025. All Rights Reserved by MedPath